Peptides for muscle growth: human evidence

01 · Continued

What the studies show.: more detail

“Peptides for muscle growth” can mean very different products. It can mean an FDA-approved medicine for one disease. It can also mean a drug in a formal study, an unapproved clinic injection, a research chemical, or a collagen supplement. Evidence for one does not automatically apply to another.

This guide asks what a study measured, who was studied, and which exact product was used. It does not provide a dose, treatment plan, eligibility decision, or treatment recommendation.

02

Start with the result a study measured.

Muscle marketing often turns one body measurement into a larger promise. A higher hormone level does not show that new muscle formed. Lean mass includes muscle, water, and other tissue that is not fat. A scan showing more muscle area does not prove greater strength, endurance, mobility, or sports performance.

The strongest evidence would come from more than one controlled study in the intended group of people. These studies would measure muscle size, strength, or daily function and would report enough follow-up and safety information. Most promoted injectable peptides do not have this evidence.

• How it might work: an effect in a cell, at a receptor, or in an animal; not a human muscle result
• Body response: a change in growth hormone (GH), IGF-1, or another body marker; not a health benefit by itself
• Body makeup: lean mass or fat-free mass, which includes water and is not the same as muscle
• Muscle structure: a scan or tissue sample that measures muscle area, volume, or fiber size
• Performance: a measure of strength, power, exercise ability, or recovery time
• Daily function: a measure of mobility, independence, symptoms, or return to usual activity

03

CJC-1295 and ipamorelin: hormone changes are not muscle growth.

CJC-1295 is a changed, longer-acting version of growth hormone-releasing hormone, a body signal. Two small studies assigned healthy adults to groups by chance. They compared several study doses with a placebo, an inactive comparison. The studies found lasting increases in growth hormone (GH) and insulin-like growth factor 1 (IGF-1). They measured how the substance moved through the body, hormone levels, and short-term side effects. They did not measure muscle size, strength, response to training, or physical function.

A larger hormone signal does not prove a health benefit. Research on growth hormone itself shows why lean-mass claims need care.

A review combined controlled studies in healthy, physically fit young people. It found more lean body mass but no clear improvement in strength or exercise ability. It also found more fluid swelling and fatigue. A later controlled study found that some extra lean mass was water outside the cells. Most performance measures did not improve. One sprint result improved for a short time.

Those growth-hormone studies did not test CJC-1295. They cannot show whether CJC-1295 has the same effects. They do show why “raises GH” does not mean “builds useful muscle.” The CJC-1295 controlled human studies in this guide have not shown better muscle growth, strength, or function.

Marketing pages often group ipamorelin, GHRP-2, GHRP-6, and similar substances with CJC-1295. A study in people or a hormone response is not a muscle-growth result. A registered ipamorelin study addressed recovery of gut function after bowel surgery. It did not show muscle growth or strength in healthy adults.

Neither CJC-1295 nor ipamorelin has an FDA-approved drug product. Neither has an approved use for muscle growth. A clinic menu does not change that status or provide the missing evidence.

A study of one ingredient does not prove that a two-ingredient product works. Two ideas about how substances might act also do not become a measured health result. This review found no completed controlled human study of the CJC-1295 and ipamorelin combination for body-building claims. No such study showed more muscle, strength, or function.

FDA's current compounding-risk page says human data for CJC-1295 are limited. It reports serious events linked with CJC-1295. These include increased heart rate and a systemic vasodilatory reaction, which means blood vessels widen across the body. For some injected forms of ipamorelin acetate, FDA says it lacks enough information to know whether the drug would cause harm. These statements describe uncertainty. They do not rank one product as safer than another.

04

Tesamorelin is approved for a narrow use, not general muscle gain.

Tesamorelin shows why approval must stay tied to one product and use. Its current FDA label covers reducing excess abdominal fat in adults with HIV and lipodystrophy, which causes unusual changes in body fat. The label says the product is not for weight-loss management and is weight neutral. It is not approved for body building, sports performance, or general age-related muscle loss.

A later analysis of earlier studies reported changes in trunk-muscle area and density in people with HIV and abdominal obesity. The analysis included only tesamorelin participants who had already reached a set reduction in deep abdominal fat. The comparison group was not selected by the same rule after treatment started.

This comparison no longer kept the original groups that were assigned by chance. It also did not show better strength, performance, or daily function. The authors said more research was needed on long-term results, daily life, and people without HIV. The study does not show a general muscle-growth benefit for healthy adults.

The label also lists reasons not to use the product and serious warnings. These cover active cancer, damage to the brain system that controls growth hormone, high IGF-1, fluid buildup, blood-sugar problems, and serious allergic reactions. FDA approved one product for a narrow use. This does not support an unapproved use or a different compounded product.

05

BPC-157 and TB-500: recovery claims are not muscle-growth proof.

BPC-157 and TB-500 are often promoted with injury-healing or “recovery” stories. Less pain, tendon repair, wound healing, return to training, muscle growth, and strength are different results. Evidence for one does not prove another.

A small Phase 1 study of BPC-157 safety and how it moved through the body was registered years ago. Phase 1 is an early safety stage. Its ClinicalTrials.gov status is unknown, and the record has no posted results. The record does not show muscle repair or growth. FDA found no or only limited safety information for the proposed routes. FDA also lacks enough information to know whether compounded BPC-157 would cause harm.

For the TB-500 fragment, FDA found no data from people who received it in drug products. FDA also lacks important safety information. Research on full-length thymosin beta-4, animal tissue repair, or lab actions does not automatically apply to the short fragment sold as TB-500. The evidence in this guide does not include a controlled human study showing better muscle growth or strength from BPC-157 or TB-500.

06

PEG-MGF, IGF-1 analogues, and follistatin: early-stage claims.

Names such as PEG-MGF, IGF-1 LR3, and follistatin come from real body pathways involved in growth and muscle control. A pathway name is not a health result. A chemical change can affect how a substance moves through the body and how it acts. It can also affect impurities and risks. Evidence about natural IGF-1, mechano growth factor, or full proteins does not automatically apply to a changed product with a related name.

FDA says it has not found data from people who received drug products containing PEG-MGF. FDA also lacks enough information to know whether PEG-MGF would cause harm. In one warning letter, FDA listed products made with follistatin and IGF1-LR3 as unapproved drugs. The products did not meet the compounding exceptions cited in that letter.

This review found no controlled human studies showing that retail versions of these products improve muscle size, strength, or function.

“No adequate controlled human evidence found” does not mean “proven ineffective.” It means good human studies have not shown enough to estimate a benefit or compare it with possible harm.

07

Collagen peptides are a separate supplement question.

Hydrolyzed collagen peptides are food-based protein ingredients taken by mouth. They are not the same as injected hormone-like drugs or research chemicals. One small study assigned older men with age-related muscle loss to groups by chance. It found differences in fat-free mass and strength when collagen was added to supervised strength training. Both groups trained. The result applies to one supplement, one group, and one training program. It does not show that a drug-like peptide builds muscle without training.

The result also depends on who was studied and what the other group received. Usual protein intake, study methods, study size, funding, and repeat studies also matter. One study does not prove that all collagen products work. A result for dietary collagen also does not prove that CJC-1295, BPC-157, TB-500, or another injection works.

Safety concerns about an unapproved injection also do not automatically apply to a common food-based supplement. The broad word “peptide” is not useful unless the product category is clear.

08

Product identity and safety are part of the evidence.

Known: a published study supports only the product and study plan that researchers used. A vial with the same ingredient name can differ in sequence, chemical form, amount, inactive ingredients, impurities, storage, or route. A route is how a product enters the body. Sterility and stability controls can also differ. A “research use only” lab report is not FDA approval. It does not prove a health benefit, sterility, or that a product is suitable for injection.

Known: compounded drugs can meet a real patient need when an approved product is not medically suitable. Compounded drugs are not FDA-approved. FDA does not review each one for safety, effectiveness, or quality before marketing. This does not mean every compounded preparation is defective. It means evidence for an approved product does not automatically apply to it.

Unknown: short studies of hormone levels cannot rule out uncommon harms or show long-term tradeoffs. For unapproved peptides with little or no human exposure information, both benefit and harm remain uncertain. Do not apply an approved-product study or a lack of reported problems to a different vial.

09

Tested athletes have separate, current anti-doping rules.

The World Anti-Doping Agency (WADA) sets rules for athletes covered by its code. Its 2026 Prohibited List took effect on January 1, 2026. Section S0 prohibits non-approved drugs such as BPC-157.

Section S2 names several groups. These include drugs made to act like growth hormone-releasing hormone, such as CJC-1295, sermorelin, and tesamorelin. It also names substances that signal the body to release growth hormone, such as ipamorelin. It covers growth factors and related substances. Examples include mechano growth factors, follistatin, and thymosin-beta-4 derivatives such as TB-500. These groups are prohibited at all times, not only during competition.

This article cannot clear a substance or product for tested sport. A prescription, clinic statement, or ingredient label does not prove that WADA permits it. A broad group can prohibit a substance even if the list does not name it as an example. A prescription alone does not grant a therapeutic use exemption. This exemption is formal permission for a necessary medical use.

A product label also does not prove that the contents match the label. Rules can change, and a sport can add requirements. Athletes and support staff should check the current WADA list and their anti-doping organization's rules. This article was checked against the 2026 list on August 2, 2026.

10

A six-question claim check is better than a ranked peptide list.

Write the sales claim in words that can be measured. “Supports muscle” is too vague. A useful claim names the exact product and people. It also names the study length, comparison group, measured result, and size of the change. Then check whether the cited human study matches each part.

A result in cells or animals does not prove muscle growth or strength in people. Neither does a change in GH, IGF-1, or lean mass. A study of an approved product does not validate a research vial. A trial registration with no posted results is not a positive result. If the source and sales claim measured different things, the claimed benefit is not established.

• Exact molecule, chemical form, finished product, and how it enters the body
• Approved product, lawful compounded preparation, study drug, research chemical, or food supplement
• People in the study compared with people targeted by the sales claim
• Direct muscle-size, strength, or function result, not only a body marker
• Controlled human results, study length, size of the change, uncertainty, and unwanted events
• Current FDA status and, for tested sport, the current prohibited list